View All

All Publications for Dr. Richard Rozek

Investment Incentives Created by the Montreal Protocol and FDA Policy on Albuterol	Published Article 2003-11-20	By Dr. Richard Rozek et al.
The Impact on Patients and Payers of Designating Albuterol a Non-Essential Use of an Ozone Depleting Substance	Regulatory Filing 2003-09-09	By Dr. Richard Rozek with former NERA Consultant Emily Bishko Radel
Broad-Based Compulsory Licensing of Pharmaceutical Technologies: Unsound Public Policy	Published Article 2001-07-01	By Dr. Richard Rozek et al.
The WTO Dispute Settlement Mechanism: TRIPS Rulings and the Developing Countries: Prospects After Seattle	Published Article 2001-03-01	By Dr. Richard Rozek
The Effects of Compulsory Licensing on Innovation and Access to Health Care	Published Article 2000-11-01	By Dr. Richard Rozek
Valuing Intellectual Property Assets for Licensing	Published Article 2000-06-01	By Dr. Richard Rozek
Transfer Prices for the Intangible Property Embodied in Products with Extraordinary Profit Potentials	Published Article 1999-10-01	By Dr. Richard Rozek et al.
The TRIPS Agreement and Access to Health Care	Published Article 1999-09-01	By Dr. Richard Rozek with Nicola Tully
The Costs to the US Health Care System of Extending Marketing Exclusivity for Taxol	Published Article 1999-09-01	By Dr. Richard Rozek
Regulatory Influences on the Decision to Introduce Pharmaceutical Products in Japan	Published Article 1998-09-01	By Dr. Richard Rapp and Dr. Richard Rozek with Gakushuin University Professor of Economics Tshuruhiko Nambu
< Back 1 2 3 Next >

NERA Economic Consulting

All Publications for Dr. Richard Rozek